Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) reported insider sales by its chief financial officer that totaled $882,028 across two trades executed on April 15 and April 16, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The filing shows Scott M. Giacobello sold 77,000 shares at $3.86 per share on April 15. The next day he sold an additional 141,600 shares at $4.13 per share. Combined, the two transactions accounted for 218,600 shares of common stock.
The disclosure states the sales were broker-assisted and were carried out to satisfy tax withholding obligations arising from the vesting of restricted stock units. Following these dispositions, Giacobello is reported to directly own 295,224 shares of Whitehawk Therapeutics. That total includes 11,822 shares obtained between November 14, 2022 and November 15, 2025 under the company’s 2021 Employee Stock Purchase Plan.
On the market, Whitehawk’s shares have experienced substantial movement over the past year, rising 162% year-over-year and gaining 21% in the prior week. At the time of the filing the stock was trading at $4.11 and the company had a market capitalization of $196.57 million.
Market data cited in the filing notes that, according to InvestingPro, the stock appears undervalued on a Fair Value basis. The InvestingPro reference is presented as an available assessment for investors seeking additional valuation context.
Separately, Whitehawk has recent clinical and coverage developments. The company presented data at the Society of Gynecologic Oncology 2026 Annual Meeting focused on its MUC16 target for ovarian cancer. That analysis, performed with Tempus AI, indicated that MUC16 expression in ovarian cancer samples is significantly higher than expression of other antibody-drug conjugate targets examined, and that MUC16 expression remained stable across stages and conditions of high-grade serous ovarian carcinoma.
On the analyst front, Citizens initiated coverage of Whitehawk Therapeutics with a Market Outperform rating and set a price target of $8.00. Citizens’ valuation approach cited in the initiation combined cash-per-share and platform value considerations.
Whitehawk’s development pipeline currently includes three antibody-drug conjugates directed at PTK7, MUC16 and SEZ6. The combination of insider filing details, clinical presentation at SGO and analyst initiation offers multiple discrete data points about the company’s recent activity and market positioning.
Clear summary - Whitehawk’s CFO sold 218,600 shares on April 15-16, 2026 for $882,028 to meet tax withholding on vested RSUs; he retains 295,224 shares. The company reported MUC16 expression data at SGO 2026 and received a Market Outperform initiation with an $8 target from Citizens.